RP902 Targets ApoE ε4 Carriers
On May 19, 2026, Risen Pharma announced the initiation of a Phase 2 clinical trial for its drug RP902 in China. This trial aims to address mild cognitive impairment due to Alzheimer’s disease. The company focuses on developing therapeutics that are accessible to patients with high medical needs.
This study is designed as a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of RP902. The primary endpoint is the change from baseline in the Clinical Dementia Rating Scale–Sum of Boxes (CDR-SB) score.
Professors Yi Tang and Yongjun Wang, affiliated with Capital Medical University, lead the study from Xuanwu and Beijing Tiantan Hospitals. Their expertise is instrumental in guiding the trial’s progress.
Understanding RP902’s Mechanism
RP902 is an oral small-molecule drug developed for patients with mild cognitive impairment due to Alzheimer’s, specifically targeting apolipoprotein E ε4 (ApoE ε4) carriers. These individuals often experience earlier onset and faster disease progression.
Preclinical studies demonstrate RP902’s capability to inhibit neurotoxic Aβ oligomers and improve cognitive function. The drug has completed Phase 1 trials with positive safety and tolerability profiles. The Phase 2 study, registered under NCT07579884, aims to further assess its potential.
RP902 offers a differentiated treatment option with its oral administration, potentially delaying disease progression for Alzheimer’s patients carrying the ApoE ε4 allele. Compared with existing therapies, it has a favorable safety profile.
In China, Alzheimer’s affects 6.0% of those aged 65 and above, roughly 1 in 17 individuals. This underscores the urgent need for effective therapies.
Risen Pharma is committed to developing accessible therapeutics for neurodegenerative diseases. The company utilises small molecules, PROTACs, and siRNA technologies to create a comprehensive therapeutic platform. With over 20 innovative drug candidates advanced, Risen Pharma aims to combat disorders like Alzheimer’s by leveraging strong in-house research and development capabilities.
